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In mice, administration of murine anti-myeloperoxidase
(MPO) IgG induces pauci-immune necrotizing crescentic
glomerulonephritis. Recent studies in this model indicate a
crucial role for complement activation in disease induction.
Here, we investigated the effect of pretreatment or
intervention with a C5-inhibiting monoclonal antibody
(BB5.1) in the mouse model of anti-MPO IgG-induced
glomerulonephritis. Mice received BB5.1 8 h before or 1 day
after disease induction with anti-MPO IgG and
lipopolysaccharide. Mice were killed after 1 or 7 days. Control
antibody-pretreated mice developed hematuria, leukocyturia
and albuminuria, and glomerulonephritis with a mean of
21.078.8% glomerular crescents and 12.875.5% glomerular
capillary necrosis. BB5.1 pretreatment prevented disease
development, as evidenced by the absence of urinary
abnormalities, a marked reduction in glomerular neutrophil
influx at day 1 and normal renal morphology at day 7.
Importantly, BB5.1 administration 1 day after disease
induction also resulted in a marked attenuation of urinary
abnormalities and a more than 80% reduction in glomerular
crescent formation. In conclusion, inhibition of C5 activation
attenuates disease development in a mouse model of anti-
MPO IgG-induced glomerulonephritis. These results favor
further investigations into the role of complement
activation in human MPO-anti-neutrophil cytoplasmic
autoantibody-mediated glomerulonephritis, and indicate
that inhibition of C5 activation is a potential therapeutic
approach in this disease.
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Wegener’s granulomatosis, Churg-Strauss syndrome, micro-
scopic polyangiitis, and pauci-immune necrotizing crescentic
glomerulonephritis (NCGN) are small vessel vasculitides
(SVVs) characterized by vascular inflammation predomi-
nantly affecting the capillaries, the precapillary arterioles, and
the post-capillary venules.1 In many cases, renal and
pulmonary involvement results in severe renal failure and
pulmonary hemorrhage which may be fatal if left untreated.
Current therapy consists mainly of immunosuppression with
high-dose corticosteroids and cyclophosphamide during the
induction phase and azathioprine in combination with low-
dose steroids as maintenance therapy. However, considerable
treatment-related morbidity and failure to induce or
maintain remission underline the importance of less toxic
and more effective therapies.
In many cases, SVVs are associated with anti-neutrophil
cytoplasmic autoantibodies (ANCAs).2 The main autoanti-
gens in ANCA-associated vasculitis are myeloperoxidase
(MPO) and proteinase 3, proteins that are predominantly
stored in the azurophilic granules of resting neutrophils.
In vitro studies suggest a crucial role for MPO-ANCA and
proteinase 3-ANCA in the pathogenesis of ANCA-associated
SVV (reviewed by Rarok et al.3) by showing that ANCAs are
capable of inducing degranulation and a respiratory burst in
tumor necrosis factor alpha (TNFa)-pretreated neutrophils,
resulting in damage of bystander endothelial cells.4 Definite
proof of the pathogenicity of MPO-ANCA came with the
development of an experimental animal model of anti-MPO-
induced NCGN that involves the transfer of mouse MPO-
reactive splenocytes or IgG into MPO-competent mice.5
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These mice developed NCGN with pathological features
similar to human anti-MPO-associated glomerulonephritis.
Further support for MPO-ANCA pathogenicity is provided
by a recently developed rat model, in which immunization of
WKY rats with human MPO led to the generation of anti-
human MPO antibodies that cross-reacted with rat MPO and
caused a mild form of NCGN.6
In the mouse model of anti-MPO IgG-induced NCGN, we
recently showed that circulating neutrophils are crucial in
disease development,7 and demonstrated that disease severity
was markedly aggravated by the addition of bacterial
lipopolysaccharide (LPS) as a proinflammatory stimulus.8
Moreover, the disease enhancing effects of LPS could be
attenuated, but not fully prevented, by pretreatment of the
animals with a TNFa bioactivity-inhibiting monoclonal
antibody (moAb). The partial response on TNFa-bioinhibi-
tion observed in this study, as well as the ambiguous results
obtained from human studies on anti-TNFa therapy in
patients with ANCA-associated vasculitis,9,10 suggests that
other factors are likely to be more critically involved in the
induction of anti-MPO-mediated NCGN. Recent experi-
ments in mouse strains deficient for various factors of the
complement system have indicated a crucial role for the
alternative pathway of complement activation in disease
induction.11 More specifically, in these studies it was found
that factor B as well as C5-deficient mice are completely
protected from anti-MPO antibody-induced NCGN, whereas
C4-deficient mice are not. These observations prompted us
to investigate whether targeting complement factor C5 is a
possible therapeutic strategy for intervention. To this end,
this study was designed to examine the effects of a C5-
inhibiting moAb in the mouse model of anti-MPO IgG-
induced NCGN.
RESULTS
Inhibition of C5 activation prevents NCGN induced by
anti-MPO IgG and LPS
Urinalysis. Upon administration of anti-MPO IgG and
0.5 mg/g LPS, mice in both groups developed similar levels
of circulating MPO-ANCA (data not shown). Control-
pretreated mice developed hematuria and leukocyturia that
lasted from day 1 until killing on day 7 (Figure 1a and b).
Urinary albumin concentrations were within normal range
on day 1 post-induction (mean 48 (range, 10–145) mg/16 h),
but were markedly increased on day 7 (mean 1600 (range,
430–3300) mg/16 h, Figure 1c). In contrast, urine samples of
mice pretreated with anti-C5 antibody displayed only
minimal amounts of blood and leukocytes throughout the
experiment (Figure 1a and b), and albuminuria was within
normal range (day 1: mean 45 (range, 6–100) mg/16h and day
7: mean 23 (range, 14–42) mg/16h; Figure 1c). At killing,
creatinine and blood urea nitrogen levels were within normal
range in all mice.
Light microscopy. In mice pretreated with control anti-
body, the administration of anti-MPO IgG and LPS induced
a focal and segmental crescentic glomerulonephritis on day 7
in all subjected mice. Although the majority of glomeruli
appeared unaffected, glomerular crescent formation and
necrosis were frequently observed. The mean percentage of
crescentic glomeruli was 21.078.8, whereas 12.875.5% of
glomeruli showed fibrinoid necrosis (Figure 2). Crescents
were cellular, and they were partly segmental (9% of the total
number of glomeruli) and partly global (13% of total).
Accompanying the crescentic glomerulonephritis, there was
mild tubulo-interstitial inflammation, which in some cases
was accompanied by mild tubular atrophy. Arterioles and
larger blood vessels were unaffected.
In contrast, glomerular crescents and fibrinoid necrosis
were completely absent in mice pretreated with C5-inhibiting
antibody (Figure 2). In addition, no tubulo-interstitial
inflammation or tubular atrophy could be found in these
mice. Phenotypic analysis of the inflammatory cell infiltrate
on day 7 revealed that anti-C5 pretreatment significantly
inhibited glomerular influx of CD45þ leukocytes, CD3þ
T cells, FA11þ macrophages, and NimpR14þ neutrophils
(Table 1).
To gain more insight into the mechanism by which anti-
C5 antibodies affect disease development in the mouse model
of anti-MPO IgG-induced NCGN, we investigated the effect
of anti-C5 pretreatment on early glomerular neutrophil
influx. Compared to the control antibody, anti-C5 antibody
pretreatment significantly reduced the number of neutrophils
per glomerular cross-section in mice 1 day after disease
induction with anti-MPO IgG and LPS (2.570.66 vs
0.7970.27/gcs, Po0.01; Figure 3).
Immunofluorescence. Immunofluorescence staining for
complement factors C1q, C3, and C4 in anti-MPO/LPS-
treated and untreated C57Bl/6 mice killed at day 1 showed
sparse glomerular staining for C1q and weak mesangial
staining for C3 in all mice (Figure 4). Also, mesangial C4
deposits were observed. The intensity and pattern of C1q, C3,
and C4 staining was similar to that observed in untreated
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Figure 1 | Pretreatment with anti-C5 moAb inhibits induction of
urinary abnormalities by anti-MPO IgG and LPS. (a) hematuria,
(b) leukocyturia, and (c) albuminuria. Open squares: control
pretreatment; filled triangles: anti-C5 pretreatment. The mean
albumin level in urine samples from untreated C57bl/6 (n¼ 5) mice
was 43 (range 26–79) mg/16 h. *Po0.05.
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C57Bl/6 mice (Figure 4). In contrast, glomerular capillary
staining for C1q, C3, and C4 was detected in renal sections
from mice 1 day after induction of heterologous anti-
glomerular basement membrane (GBM) glomerulonephritis
(Figure 4). In these mice, staining for C5 demonstrated
moderate granular glomerular deposits. However, such
deposits were not detected in untreated C57Bl/6 mice and
anti-MPO/LPS-treated mice. Immunofluorescence staining
for IgG revealed only scant deposits of IgG in glomeruli in all
mice (data not shown).
Inhibition of C5 activation after disease induction attenuates
NCGN induced by anti-MPO IgG and LPS
Urinalysis. We next investigated whether anti-C5 treatment
was also beneficial when administered 1 day after the
induction of disease with anti-MPO IgG and LPS. We
previously demonstrated that at this time point, considerable
glomerular neutrophil influx is already present.8 Moreover, at
the start of intervention, mice in both groups had similar
levels of circulating anti-MPO antibodies and had developed
hematuria and leukocyturia to a similar extent (Figure 5a and
b). As shown in Figure 5a, the extent of hematuria declined
in mice treated with a single dose of BB5.1, and was absent
on day 5. At the time of killing on day 7, three out of six
BB5.1-treated animals were still free from hematuria, whereas
hematuria persisted in control-treated animals.
Anti-C5 treatment also had a pronounced effect on
leukocyturia. In control antibody-treated mice, leukocyturia
increased during the time course of the experiment, whereas
this increase was absent in mice treated with anti-C5
antibody (Figure 5b). In both groups, albuminuria was
quantified in urine samples obtained on day 1 and day 7
post-induction. As shown in Figure 5c, urinary albumin
levels on day 1 were within normal range in both groups. On
day 7, however, a significant increase in albuminuria was
detected in control antibody-treated mice, whereas in anti-C5
antibody-treated mice urinary albumin levels were only
minimally elevated (mean 212 (range, 45–633)mg/16 h in
anti-C5 antibody-treated mice vs 1596 (range, 705–2552) mg/
16 h in control antibody-treated mice, Po0.01).
Light microscopy. On day 7, all control antibody-treated
mice had developed a focal and segmental NCGN, with a
mean of 13.974.5% crescentic glomeruli, and 11.873.4% of
glomeruli displaying capillary fibrinoid necrosis. The develop-
ment of NCGN was, however, markedly attenuated in the
anti-C5 antibody-treated mice, showing a mean of 1.970.8%
glomerular crescents, and 1.571.2% of the glomeruli
containing capillary fibrinoid necrosis (Figure 6).
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Figure 2 | Pretreatment with anti-C5 moAb prevents development of NCGN induced by anti-MPO IgG and LPS. (a) Overview of renal
cortical tissue from a control antibody pretreated mouse, 7 days after administration of anti-MPO IgG and LPS, representing the focal and
segmental nature of the glomerulonephritis. Glomerular crescents are indicated by arrowheads. (b) Overview of renal cortical tissue from an
anti-C5 moAb-treated mouse, 7 days after administration of anti-MPO IgG and LPS, displaying normal renal morphology. (c) Detail of a
glomerulus with a large cellular crescent from a mouse that received anti-MPO IgG and LPS after pretreatment with control antibody. (d) Detail
of a glomerulus from a mouse that received anti-MPO IgG and LPS after pretreatment with anti-C5 moAb, displaying normal morphology.
(e) Effect of pretreatment with anti-C5 moAb on glomerular crescent formation expressed as a percentage of glomerular crescents in individual
mice. (f) Effect of pretreatment with anti-C5 moAb on glomerular necrosis expressed as a percentage of glomeruli with capillary necrosis
in individual mice. Horizontal lines represent mean percentages in each group. (a–d) Periodic acid Schiff’s stain. Original magnification:
(a and b)  200; (d and e)  630.
Table 1 | Immunophenotyping of intraglomerular
inflammatory cell infiltrate at 7 days after pretreatment with
anti-C5 moAb (BB5.1) or isotype control moAb (ENA-1)
Control-
pretreatmenta
(n=5)
Anti-C5
pretreatmenta
(n=5) P-value
CD45+ leukocytes 3.270.59 1.270.21 0.0004
CD3+ T cells 0.4570.11 0.1370.05 0.0011
FA11+ macrophages 2.370.62 0.6870.32 0.002
NIMP-R14+ neutrophils 0.4170.12 0.2270.09 0.03
moAb, monoclonal antibody.
aNumber of cells (mean7s.d.) per glomerular cross-section.
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Also, treatment with the C5-inhibiting antibody led to a
significant reduction in glomerular influx of CD45þ
leukocytes as well as CD3þ T cells and FA11þ macrophages
on day 7 (Table 2). In both groups, glomerular influx of
NIMP-R14þ neutrophils on day 7 was low and the difference
between the groups did not reach statistical significance
(Table 2). Staining for complement proteins in these groups
of mice was similar to those of the pretreatment study. There
were no differences in C1q, C3, C4, and C5 staining between
BB5.1-treated and control-treated mice, and the intensity and
pattern in both groups were similar to the untreated C57bl/6
mice (data not shown).
DISCUSSION
In this study, we demonstrate that mice pretreated with
BB5.1, a moAb that inhibits activation of complement factor
C5, are completely protected from disease induced by anti-
MPO IgG and 0.5 mg/g bacterial LPS. Control-pretreated
mice developed focal segmental NCGN to a degree compar-
able with our previous observations.8 Importantly, we also
demonstrate that intervention with BB5.1 after the onset of
disease, at a time that important signs of disease, such as
hematuria, leukocyturia, and glomerular influx of neutro-
phils, are already present, was also effective, as evidenced by a
more than 80% reduction in the percentage of crescentic
glomeruli and a more than 85% reduction in albuminuria on
day 7.
Our study is the first to show that C5-inhibition prevents
disease development in an animal model of ANCA-mediated
NCGN. These results are in line with two other studies on
immune-mediated glomerular injury showing involvement
of the terminal complement pathway in a mouse model of
lupus nephritis12 and glomerulonephritis induced by cryo-
globulins.13 According to the currently prevailing theory on
the pathogenesis of ANCA-mediated vasculitis (reviewed by
Heeringa et al.14), ANCA-induced activation of primed
neutrophils is crucial to disease development. ANCA-
activated neutrophils adhere to susceptible vascular endothe-
lium, where they release oxygen radicals and lytic granule
constituents, leading to local inflammation. Although this
theory has proven very useful, it does not explain the critical
involvement of complement in ANCA-induced disease.
Complement system activation can occur through the
classical pathway, which is dependent on immune complexes
(ICs), through the mannose-binding lectin (MBL) pathway,
or through alternative pathway activation. Because of the
paucity of ICs in renal biopsies from patients with ANCA-
associated NCGN, it seems unlikely that the classical pathway
plays an important pathogenic role. Immune deposits have,
however, been found in fresh skin lesions from Wegener’s
granulomatosis patients, suggesting their involvement in the
initial phase of disease development.15 Moreover, IC deposi-
tions were found in over 50% of renal biopsies from ANCA-
associated vasculitis patients16 and their presence was
associated with higher levels of proteinuria. This association
does, however, not reveal whether IC positivity is the cause of
more severe disease manifestations, or whether it is merely
the result of more severe disease. Finally, we previously
reported that levels of circulating MPO in mice are increased
upon treatment with LPS, which could potentially lead to the
formation of circulating MPO/anti-MPO ICs in our model.8
However, whether circulating ICs are formed and whether
these participate in disease induction is unknown at present
and warrants further investigation. In this respect, it is
important to note that C4-deficient mice, which are unable
to activate the classical complement pathway, are not
protected from disease induced by anti-MPO IgG.11 More-
over, in our this study, glomerular depositions of IgG and
C1q were scanty and not different from those observed in
untreated mice. Together, these results suggest that disease
development in the mouse model of anti-MPO IgG-induced
NCGN is not dependent on activation of the classical
pathway of complement activation.
Involvement of the MBL pathway of complement activa-
tion has been demonstrated in several forms of glomerulone-
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Figure 3 | Pretreatment with anti-C5 moAb significantly reduces
early glomerular neutrophil influx. (a) Glomerulus from a mouse
that had received anti-MPO IgG and LPS and was pretreated with
control antibody demonstrating marked segmental infiltration of
neutrophils as detected by immunohistochemistry. (b) Glomerulus
from a mouse that had received anti-MPO IgG and LPS and was
pretreated with anti-C5 moAb, demonstrating strongly reduced
neutrophil infiltration. (c) Quantification of glomerular neutrophil
influx 1 day of administration of anti-MPO IgG and LPS in mice that
were pretreated with control antibody (white bar) or anti-C5 moAb
(black bars). gcs, glomerular cross-section; original magnification:
(a and b)  630. **Po0.01.
Kidney International (2007) 71, 646–654 649
D Huugen et al.: Anti-C5 treatment in anti-MPO IgG-induced NCGN o r i g i n a l a r t i c l e
phritis, including IgA nephropathy and lupus nephritis.17
However, whether MBL pathway activation contributes to
ANCA-mediated SVV is largely unknown and has not been
thoroughly investigated. A recent study showed that in
patients with ANCA-associated vasculitis, genotype frequen-
cies of polymorphic variants in the MBL gene are not
different from those observed in the normal population
(Kamesh L, Heward JM, Williams JM et al. Kidney Blood Press
Res 2005; 28: 176, abstract). Moreover, mice deficient for C4,
one of the key components of the MBL cascade, are not
protected from disease induction in the model of anti-MPO
IgG-induced NCGN.11 Together, these data indicate that
involvement of the MBL pathway in ANCA-mediated SVV is
unlikely.
The initiating event in the alternative pathway of the
complement cascade is the spontaneous generation of the C3
convertase, C3bBb. This complex is, however, very unstable,
and its proper functioning is therefore dependent on the
stabilizing effect of the binding of properdin. Interestingly, it
has been shown that properdin is one of the proteins that is
released by activated neutrophils.18 Stabilizing the C3
convertase and consequent potentiation of the complement
cascade might therefore be an important additional delete-
rious effect of neutrophil activation in ANCA-associated
vasculitis. However, very little is known about the C3-binding
and activating properties of ANCA. In one study, ANCA-
positive sera were found to facilitate the binding of
complement factor C3c, as well as the formation of C5b-9,
on neutrophils.19 Bearing in mind the results of our study,
this potential mechanism of direct ANCA-induced comple-
ment activation certainly merits further investigations.
The enzymatic activity of MPO and other neutrophil
lysosomal constituents may provide an alternative – or
additional–link between MPO-ANCA and complement
activation. It has been shown that C5 can acquire neutrophil
chemotactic activity upon treatment with an enzyme stored
in the lysosomal granules of granulocytes, but the nature of
this enzyme remains unclear.20 Interestingly, C5 acquires
C5b-like activity upon treatment with hypochlorite and
hypochlorite-modified amines, either from an exogenous
source,21 or as the enzymatic product of MPO released from
activated neutrophils.22 As the majority of MPO-ANCA do
not inhibit MPO activity, but actually prevent the inhibition
of MPO activity by its natural inhibitor, ceruloplasmin,23 it is
C57BL/6 Anti-GBM Anti-MPO/LPS
C1q
C3
C4
C5
Figure 4 | Immunofluorescence staining for complement proteins in untreated C57bl/6 mice and in mice 1 day after injection with
anti-MPO IgG and LPS or heterologous rabbit anti-GBM antibodies. Representative glomeruli stained for C1q, C3, C4, and C5 are shown.
In untreated C57Bl/6 mice and mice killed 1 day after injection of anti-MPO IgG and LPS, sparse glomerular staining for C1q, weak mesangial
staining for C3, and mesangial deposits of C4 were observed. In contrast, in mice killed 1 day after injection of rabbit anti-GBM antibodies,
capillary staining for C1q, C3, and C4 was found. For C5, moderate granular glomerular deposits were observed in renal sections of mice
subjected to accelerated sheep anti-GBM nephritis, whereas no glomerular staining was detected in untreated C57Bl/6 mice and
anti-MPO/LPS-treated mice. Original magnification (all pictures)  400.
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conceivable that release of MPO, in the presence of MPO-
ANCA, leads to MPO-induced activation of the terminal
complement pathway. It is, however, unclear in these studies
whether, during the formation of the C5b-like complex, also
a protein with C5a-like properties is formed. In addition, this
mechanism does not provide an explanation for the critical
role of alternative pathway activation in anti-MPO IgG-
induced NCGN.11
Upon activation, C5 is spliced into two cleavage products.
The C5b molecule is involved in the generation of C5b-9, the
end product of the terminal complement pathway. The C5a
molecule is a powerful chemoattractant for neutrophils, and
has considerable neutrophil activating potential. As BB5.1
inhibits C5a activity as well as the formation of C5b-9,24 its
effect on anti-MPO IgG-induced NCGN can theoretically be
caused by the inhibition of C5a activity, inhibition of C5b-9
formation, or both.
Very little is known about the role of C5b-9 in ANCA-
associated glomerulonephritis. On neutrophil smears, it has
been demonstrated that ANCA-positive sera are capable of
binding C3 which, in some cases, resulted in the formation of
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Figure 5 | Intervention with anti-C5 moAb attenuates urinary
abnormalities induced by anti-MPO IgG and LPS. (a) hematuria,
(b) leukocyturia, and (c) albuminuria. Open squares: control
treatment; filled triangles: anti-C5 treatment. **Po0.01.
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Figure 6 | Intervention with anti-C5 moAb attenuates development of NCGN induced by anti-MPO antibodies and LPS. (a) Overview of
renal cortical tissue from a control antibody treated mouse 7 days after administration of anti-MPO IgG and LPS representing the focal and
segmental nature of the induced glomerulonephritis. Glomerular crescents are indicated by arrowheads. (b) Overview of renal cortical tissue
from an anti-C5 moAb-treated mouse 7 days after administration of anti-MPO IgG and LPS. One glomerular crescent is observed (arrowhea
d). (c) Detail of a glomerulus with a cellular crescent from a mouse that received anti-MPO IgG and LPS and was treated with control antibody.
(d) Detail of a glomerulus with a small cellular crescent from a mouse that received anti-MPO IgG and LPS and was treated with anti-C5
moAb. (e) Effect of treatment with anti-C5 moAb on glomerular crescent formation expressed as a percentage of glomerular crescents in
individual mice. (f) Effect of treatment with anti-C5 moAb on glomerular necrosis expressed as a percentage of glomeruli with capillary necrosis
in individual mice. Horizontal lines represent mean percentages in each group. (a–d) Periodic acid Schiff’s stain. Original magnification:
(a and b)  200; (d and e)  630. ***Po0.001.
Table 2 | Immunophenotyping of intraglomerular
inflammatory cell infiltrate at 7 days after treatment with
anti-C5 moAb (BB5.1) or isotype control moAb (ENA-1)
Control-
treatmenta
(n=5)
Anti-C5
treatmenta
(n=6) P-value
CD45+ leukocytes 3.270.76 1.770.19 0.0011
CD3+ T cells 0.5170.20 0.1470.06 0.0017
FA11+ macrophages 1.8570.30 0.970.18 0.0001
NIMP-R14+ neutrophils 0.3770.09 0.2770.08 NS
moAb, monoclonal antibody; NS, not significant.
aNumber of cells (mean7s.d.) per glomerular cross-section.
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C5b-9.19 It is, however, unclear whether this mechanism also
plays a role in vivo. Alternatively, C5a activity could play a
critical role in the pathogenesis of MPO-ANCA-associated
vasculitis. C5a has strong neutrophil-attracting capability,
and we previously showed that, in the mouse model of anti-
MPO IgG-induced NCGN, neutrophils are crucial for disease
development.7 In our this study, we observed that anti-C5
pretreatment led to a significant decrease in early glomerular
neutrophil influx on day 1. This is in line with several studies
showing that C5a strongly promotes the adhesion of
neutrophils to endothelial cells.25,26 Being a strong neutrophil
activator, C5a might induce the adherent neutrophils to
subsequently undergo an oxidative burst and release their
granular enzymes. Interestingly, C5a is also a strong inducer
of properdin release by neutrophils,18 and might thus be part
of a positive feedback loop stabilizing the alternative pathway
convertase, thereby increasing inflammation.27
It has previously already been shown by our group that
neutrophils play a pivotal role in the pathogenesis of anti-
MPO IgG-induced NCGN.7 However, whereas macrophages
importantly contribute to glomerular lesions in this, as well
as in a previous8 study, it is as yet unclear as to what extent
these cells are involved in the pathogenic process. It has been
shown that monocytes, being the circulating precursors of
macrophages, are activated in humans with active ANCA-
associated disease,28 and in vitro studies have revealed that
ANCA themselves might be, at least partly, responsible for
this.29 Moreover, macrophages have frequently been shown to
be the predominant cell type in glomerular lesions of patients
with ANCA-associated vasculitis30,31 (reviewed by Ferrario
and Rastaldi32). These studies do, however, not unequivocally
prove a role for monocytes and macrophages in ANCA
disease. Therefore, although in our study significantly less
glomerular macrophages are observed in experimental mice
pretreated with anti-C5, and although the activating effect of
C5a on monocytes and macrophages is well known,
additional studies are required to reveal whether the observed
reduction in macrophage influx is pathogenetically involved
in the effect of anti-C5 treatment in this disease model.
Murine anti-MPO IgG-induced NCGN is in many ways
similar to MPO-ANCA-associated NCGN observed in hu-
mans. As in human disease, ICs are scarce or absent in the
mouse model,5,8 and murine anti-murine MPO IgG activates
TNFa-primed murine neutrophils.8 The results of this study
together with the observations that murine anti-MPO-
induced NCGN is dependent on an intact alternative pathway
complement system indicate a previously unsuspected role
for complement activation in ANCA-associated diseases.
Clearly, these results require confirmation and translation to
the human situation.
MATERIALS AND METHODS
Mice
Mpo/ mice, backcrossed to a C57BL/6 background for six times,
were genotyped using polymerase chain reaction-amplified DNA
from tail clippings.33 Wild-type female C57Bl/6 (8–12 weeks of age)
mice were obtained from Harlan (Horst, the Netherlands). Mice
were kept according to University of Maastricht animal facility
regulations, and all experiments were approved by the local Animal
Care and Experimentation Committee.
Purification of murine MPO
Murine MPO was purified from WEHI-3 cells as described
previously.8 Purity was checked by sodium dodecyl sulfate
polyacrylamide gel electrophoresis.
Preparation of polyclonal mouse anti-mouse MPO IgG
Mpo/ mice were immunized with murine MPO as reported
previously.8 On day 42, mice were bled. Anti-MPO antibody titers
were monitored by enzyme-linked immunosorbent assay as
described previously.8 IgG was isolated from pooled sera by 50%
ammonium sulfate precipitation followed by protein G column
affinity chromatography. IgG-containing fractions were concen-
trated by ultrafiltration (Centriplus; Millipore, Amsterdam, The
Netherlands) and dialyzed against phosphate-buffered saline.
Protein concentrations were determined using the bicinchoninic
acid protein assay kit (Pierce, Rockford, IL, USA). The anti-MPO
titer of each batch was checked by enzyme-linked immunosorbent
assay as described above, using a sample of anti-MPO IgG with
previously established pathogenicity as a reference.
Induction of glomerulonephritis with anti-MPO IgG and LPS
C57BL/6 mice received a dose of 100mg/g body weight of sterile-
filtered (0.2 mm filter; Schleicher and Schuell, Dassel, Germany) anti-
MPO IgG by intraperitoneal injection. Previously, we showed that
the administration of LPS considerably aggravated anti-MPO IgG-
induced disease resulting in a more vigorous disease model.8
Therefore, all mice received a single intraperitoneal injection with
0.5 mg/g body weight LPS (Escherichia coli, serotype 026-B6l; Sigma,
St Louis, MO, USA), 1 h after the administration of anti-MPO IgG.
Anti-C5 treatment
To inhibit C5 function, we used the mouse anti-murine C5 moAb
BB5.1. This is a murine IgG1 antibody that blocks C5a activity as
well as the formation of C5b-9 in vivo.24 ENA-1 (anti-human
E-selectin34) was used as isotype control.
In a first experiment, C57BL/6 mice were pretreated with an
intraperitoneal injection of 1 mg of sterile-filtered BB5.1 (n¼ 9) or
isotype control antibody (n¼ 9) 8 h before disease induction with
anti-MPO IgG and LPS, to investigate the effect of C5 inhibition in
the induction phase of disease. Mice were killed after 1 day (n¼ 4/
group) or after 7 days (n¼ 5/group) to evaluate disease development.
In the next experiment, we investigated whether intervention
with BB5.1 after the induction of disease would lead to attenuation
of anti-MPO IgG-induced NCGN. Disease was induced with anti-
MPO IgG and LPS as in the first experiment, but this time, 1 mg of
BB5.1 or control antibody was given 1 day after disease induction.
Mice were killed at 7 days after disease induction (n¼ 5–6/group).
In all mice, circulating anti-MPO IgG was monitored by enzyme-
linked immunosorbent assay as described above, using a serum pool
from MPO-immunized MPO-knockout mice as a reference.
Laboratory and pathological evaluation of disease
At several time points during disease development, urine samples
were tested by dipstick (Bayer, Mijdrecht, the Netherlands) for
hematuria and leukocyturia and scored on a 0–4þ scale. At the
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time points indicated, mice were placed in metabolic cages for
16 h to obtain urine for the determination of albuminuria by
enzyme-linked immunosorbent assay (Bethyl Inc., Montgomery,
TX, USA). Blood urea nitrogen and creatinine levels were
determined in sera collected at the time of killing by an enzymatic
degradation assay on a Synchron LX20 PRO (Beckman Coulter Inc.,
Fullerton, CA, USA).
Tissue samples were taken from both kidneys and processed for
light microscopy, immunofluorescence, and immunohistochemistry.
For light microscopy, renal tissue samples were fixed in 4%
formaldehyde and embedded in paraffin. Sections (1.5 mm) were
cut and hematoxylin/eosin, periodic acid Schiff, and Martius yellow-
brilliant crystal scarlet-soluble blue staining was performed accord-
ing to standard procedures. For each animal, the amount of
crescents was determined in 100 consecutive glomerular cross-
sections. Only glomeruli that had two or more layers of cells in
Bowman’s space were considered crescentic. Similarly, a glomerular
necrosis score was determined for each animal by evaluating
segmental or global glomerular capillary necrosis in 100 consecutive
glomerular cross-sections. Analysis was performed in a blinded
manner by two independent investigators.
Phenotypic analysis of the inflammatory cell infiltrate was
performed on 4-mm cryostat sections fixed in 100% acetone at room
temperature. The following primary antibodies were used: rat anti-
mouse CD45 (clone MP33), rat anti-mouse neutrophils (clone
NIMP-R14),35 rat anti-mouse CD68 (macrophages, clone FA1136),
and rat anti-mouse CD3 (clone KT3). Endogenous peroxidase
activity was blocked with 0.05% H2O2 in phosphate-buffered saline.
Rabbit anti-rat IgG-PO and goat anti-rabbit IgG-PO (both
DakoCytomation) were used as appropriate secondary and tertiary
antibodies, respectively. Antibody binding was visualized using 3-
amino-9-ethylcarbazole with H2O2 as substrate. Sections were
counterstained with hematoxylin. Glomerular cell infiltrates were
determined by counting the number of positive cells in 30
glomerular cross-sections per kidney section.
The presence of complement proteins was determined by
immunofluorescence using the following primary antibodies:
polyclonal digoxigenin-(dig-)-labeled rabbit-anti-mouse C1q (gen-
erously provided by Professor Dr MR Daha, Leiden, The Nether-
lands37), monoclonal rat-anti-mouse C4 (clone 16D2; HBT, Uden,
the Netherlands), monoclonal rat-anti-mouse C3 (clone 11H9;
HBT), and rabbit anti-mouse C5 (HBT) . Fluorescein isothiocya-
nate-labeled sheep-anti-dig IgG (Roche Diagnostics, Almere, the
Netherlands), ALEXA 568-labeled goat-anti-rat IgG, and ALEXA
568-labeled goat-anti-rabbit (Invitrogen, Breda, The Netherlands)
supplemented with 5% normal sheep serum were used as
conjugates. Deposition of mouse IgG was detected by rabbit anti-
mouse IgG-Alexa Fluor 488 (Invitrogen).
Statistical analysis
Data are expressed as mean7s.d. and were analyzed by two-tailed
Student’s t-test using Graphpad Prism 4.03 for Windows (Graphpad
Software, San Diego, CA, USA). Because of their non-Gaussian
distribution, albuminuria data were compared by the two-tailed
Mann–Whitney U-test. In both cases, Pp0.05 were considered
statistically significant.
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